Loading data for TVTX — first visit, this takes a few seconds.

Travere Therapeutics, Inc. (TVTX)

NasdaqGM: TVTX · Real-Time Price · USD

65.28

-1.26 (-1.89%)

At close: Sep 04, 2026, 8:00 PM

65.28

+0.00%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	47.37
Market Cap	6.15B
Revenue (ttm)	591M
Net Income (ttm)	-67.7M
	1.06
	-0.73
	n/a
	11.51
P/B (ttm)	61.12
P/S (ttm)	10.27
Earnings Date	Oct 29, 2026

Ask	78.79
Volume	1,050,500
Avg. Volume (20D)	1,724,944
Open	66.04
Previous Close	66.54
Day's Range	65.04 - 67.11
52-Week Range	20.84 - 68.03
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 8, 2012

Employees 497

Stock Exchange NasdaqGM

Ticker Symbol TVTX

Website https://travere.com

Full Company Profile

Financial Performance

In 2025, Travere Therapeutics's revenue was 490.73M, an increase of 110.45% compared to the previous year's 233.18M. Earnings were -25.55M, a decrease of -92.06%.

Financial Statements

Earnings Surprise

Travere Therapeutics has released their quarterly earnings on Aug 4, 2026:

Revenue of $169.58M misses estimates by $0, with 48.17% YoY growth.
EPS of -0.1 misses estimates by -0.42, with -176.92% YoY decline.

Next Earnings Release

Travere Therapeutics, Inc. is scheduled to release its earnings on Oct 29, 2026, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · Investor's Business Daily

TGTX Stock Outperforms 95% of Stocks. Here's Why.

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

2 weeks ago · Investor's Business Daily

IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'

Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy point.

2 weeks ago · Investor's Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

2 weeks ago · MarketBeat

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline

Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and buildin...

3 weeks ago · Motley Fool

Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript

FILSPARI net sales surged 96% year-over-year, driven by strong FSGS launch demand.

Page 1 of 2

Travere Therapeutics, Inc. (TVTX)